Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis

Clinical trials of biologic therapies in psoriasis usually evaluate fixed dosing regimens. It is well-known, however, that patients prescribed biologics may occasionally need to interrupt therapy for reasons such as surgery, changes in healthcare coverage, or pregnancy.1 Consequently, dermatologists need to know whether interruption of biologic therapy may be associated with diminished response upon retreatment. We analyzed data from a randomised withdrawal trial of secukinumab in subjects with moderate to severe plaque psoriasis to ascertain the effects of retreatment. This article is protected by copyright. All rights reserved.